arrow
D

Daniel C. Chambers

the prince charles hospital
H指数:52
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Non-Invasive Distal Airway Proteomics by Particles in Exhaled Air (PExA) Sampling Demonstrates Shared Proteomic Features with Matched Bronchoalveolar Lavage

通过呼出空气中的颗粒(PExA)采样进行无创远端气道蛋白质组学分析,显示出与配对支气管肺泡灌洗液共享的蛋白质组学特征

2026-09-270
OA
Multi-omics to study chronic respiratory diseases and viral infections

多组学方法研究慢性呼吸道疾病和病毒感染

2026-01-012
PRE
Do we need to prioritise interstitial lung disease clinical diagnoses? A comment on the 2025 interstitial pneumonia statement

我们需要优先考虑间质性肺疾病临床诊断吗?对2025年间质性肺炎声明的评论

2026-01-010
PRE
A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocol

一项针对间质性肺疾病患者数字自我管理方案的随机对照试验:REBUILD-SM方案

2025-12-050
OAAI
Silicosis research priorities for health care, research, and health and safety professionals, and for people exposed to silica in Australia: a research priority setting exercise

澳大利亚硅肺病研究优先事项:面向医疗保健、研究和健康安全专业人士,以及接触二氧化硅人群的研究优先事项设定研究

2025-07-290
OAAI
Transcriptomic Plasticity of Human Alveolar Macrophages Revealed by Single-Cell RNA Sequencing Following Drug Exposure: Implications for Therapeutic Development

药物暴露后由单细胞RNA测序揭示的人肺泡巨噬细胞转录组可塑性:对治疗开发的启示

2025-05-070
OA
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
2024-12-030
OAAI
Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung disease
THORAX
IF7.7
2024-09-240
PRE
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

特发性肺纤维化和进行性肺纤维化的治疗: 澳大利亚和新西兰胸科学会2023修订版的立场声明

2024-01-1115
OAAI